# NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

> **NCT04435665** · PHASE2 · COMPLETED · sponsor: **NFlection Therapeutics, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Neurofibromatosis 1
- Cutaneous Neurofibroma

## Interventions

- **DRUG:** NFX-179 Gel
- **DRUG:** Vehicle Gel

## Key facts

- **NCT ID:** NCT04435665
- **Lead sponsor:** NFlection Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-21
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-14
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435665, "NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04435665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*